Greg Harrison
Stock Analyst at B of A Securities
(4.62)
# 228
Out of 5,042 analysts
101
Total ratings
63.64%
Success rate
20.53%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $418.58 | +10.61% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $39.90 | +7.77% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $28.06 | +10.48% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $11.49 | +74.06% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $54.26 | +5.05% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $421.39 | +3.94% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $463.43 | -2.90% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $43.33 | +50.01% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.85 | +3.90% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $2.48 | +343.55% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $11.22 | +211.94% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $29.22 | +88.23% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $22.38 | +65.33% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $15.04 | +72.87% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $28.17 | -29.00% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.24 | +20.97% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $27.96 | +43.06% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $85.63 | -12.41% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $11.98 | +50.25% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $25.60 | +255.47% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $32.28 | -62.83% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.63 | +136.85% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $3.72 | +303.23% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $7.55 | -60.26% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.08 | +3,265.38% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $17.65 | +205.95% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $60.10 | +49.75% | 5 | Mar 14, 2022 |
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $418.58
Upside: +10.61%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $39.90
Upside: +7.77%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $28.06
Upside: +10.48%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $11.49
Upside: +74.06%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $54.26
Upside: +5.05%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $421.39
Upside: +3.94%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $463.43
Upside: -2.90%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $43.33
Upside: +50.01%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.85
Upside: +3.90%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.48
Upside: +343.55%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $11.22
Upside: +211.94%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $29.22
Upside: +88.23%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $22.38
Upside: +65.33%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $15.04
Upside: +72.87%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $28.17
Upside: -29.00%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.24
Upside: +20.97%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $27.96
Upside: +43.06%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $85.63
Upside: -12.41%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $11.98
Upside: +50.25%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $25.60
Upside: +255.47%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $32.28
Upside: -62.83%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.63
Upside: +136.85%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $3.72
Upside: +303.23%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $7.55
Upside: -60.26%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.08
Upside: +3,265.38%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $17.65
Upside: +205.95%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $60.10
Upside: +49.75%